…
AbbVie is selling around $15 billion of bonds in the US investment-grade market to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics…
Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help…
Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions…
AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of…
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
…
During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This…
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry…
The FDA grants priority review to ImmunoGens (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for…
…
…
AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes into the…
AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by…
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors…
…
…
Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the…
…
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of…
Immunogen shares surge on news of takeover by AbbVie…
…
…
…
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio…
AbbVie Inc. ABBV announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN in a cash deal valued…
…
Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.…
…
Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.…
ImmunoGens (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company…
Zscaler stock, AppFolio, Brown & Brown, Consol Energy and Copart are among the 29 new stocks on IBDs proprietary stock…
…
ImmunoGen (IMGN) delivered earnings and revenue surprises of 400% and 6.02%, respectively, for the quarter ended September 2023. Do the…
…
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.…
…
…
…
TOKYO (dpa-AFX) - ImmunoGen, Inc. (IMGN), a biopharmaceutical company, announced on Monday that it has entered into an exclusive collaboration…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Shares of ImmunoGen Inc. IMGN jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with…
Coen, Stacy Ann - Vorstand - Tag der Transaktion: 2023-08-09...…
Lentini, Renee - Vorstand - Tag der Transaktion: 2023-08-02...…
ImmunoGens (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
ImmunoGen Shares Fall After Medical Chief's Exit, Spending Outlook...…
ImmunoGen (IMGN) delivered earnings and revenue surprises of 87.50% and 94.09%, respectively, for the quarter ended June 2023. Do the…
Die Biotech-Schmiede Immunogen hat in diesem Jahr mit sehr starken Daten zu Elahere für Aufsehen gesorgt. DER AKTIONÄR nahm diese…
ImmunoGen Names Michael Vasconcelles Chief Medical Officer...…